Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

37 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
The Clinical Efficacy of Epoetin Alfa and Darbepoetin Alfa in Patients with Low-Risk or Intermediate-1-Risk Myelodysplastic Syndrome: Retrospective Multi-center Real-Life Study.
Ak MA, Sahip B, Geduk A, Ucar MA, Kale H, Hacibekiroglu T, Polat MG, Kalpakci Y, Bolaman AZ, Guvenc B, Ertop S. Ak MA, et al. Among authors: hacibekiroglu t. Indian J Hematol Blood Transfus. 2022 Apr;38(2):299-308. doi: 10.1007/s12288-021-01458-1. Epub 2021 Jun 26. Indian J Hematol Blood Transfus. 2022. PMID: 35496974 Free PMC article.
Long-Term Efficacy of Erythropoiesis-Stimulating Agents in Patients with Low-Risk or Intermediate-1-Risk Myelodysplastic Syndrome: Multicenter Real-Life Data.
Aslaner Ak M, Gedük A, Acar İH, Polat MG, Sunu C, Bolaman AZ, Hacıbekiroğlu T, Güvenç B, Ertop Ş. Aslaner Ak M, et al. Among authors: hacibekiroglu t. Turk J Haematol. 2023 May 29;40(2):92-100. doi: 10.4274/tjh.galenos.2023.2022.0437. Epub 2023 Feb 17. Turk J Haematol. 2023. PMID: 36799095 Free PMC article.
Efficacy and safety of the neonatal Fc receptor inhibitor efgartigimod in adults with primary immune thrombocytopenia (ADVANCE IV): a multicentre, randomised, placebo-controlled, phase 3 trial.
Broome CM, McDonald V, Miyakawa Y, Carpenedo M, Kuter DJ, Al-Samkari H, Bussel JB, Godar M, Ayguasanosa J, De Beuf K, Rodeghiero F, Michel M, Newland A; ADVANCE Investigator Study Group. Broome CM, et al. Lancet. 2023 Nov 4;402(10413):1648-1659. doi: 10.1016/S0140-6736(23)01460-5. Epub 2023 Sep 28. Lancet. 2023. PMID: 37778358 Clinical Trial.
Real-world data on the effectiveness and safety of Ixazomib-Lenalidomide-Dexamethasone therapy in relapsed/refractory multiple myeloma patients: a multicenter experience in Turkey.
Bakırtaş M, Dal MS, Yiğenoğlu TN, Giden AO, Serin I, Başcı S, Kalpakci Y, Korkmaz S, Ekinci O, Albayrak M, Basturk A, Ozatli D, Dogu MH, Hacıbekiroglu T, Çakar MK, Ulas T, Miskioglu M, Gulturk E, Eser B, Altuntas F. Bakırtaş M, et al. Among authors: hacibekiroglu t. J Chemother. 2023 Oct;35(6):563-569. doi: 10.1080/1120009X.2023.2208439. Epub 2023 May 21. J Chemother. 2023. PMID: 37211906
International Forum: The Turkish perspective on apheresis activity: The Turkish apheresis registry report.
Ozatli D, Giden AO, Erkurt MA, Korkmaz S, Basci S, Ulas T, Turgut B, Yigenoglu TN, Hacibekiroglu T, Basturk A, Dal MS, Namdaroglu S, Hindilerden F, Hacioglu SK, Cagliyan GA, Ilhan G, Kacmaz M, Uysal A, Merter M, Ekinci O, Dursun FE, Tekinalp A, Demircioglu S, Sincan G, Acik DY, Akdeniz A, Ucar MA, Yeral M, Ciftciler R, Teke HU, Umit EG, Karakus A, Bilen Y, Yokus O, Albayrak M, Demir C, Okan V, Serefhanoglu S, Kartı S, Ozkurt ZN, Eser B, Aydogdu I, Kuku I, Cagirgan S, Sonmez M, Ozet G, Altuntas F. Ozatli D, et al. Among authors: hacibekiroglu t. Transfus Apher Sci. 2023 Apr;62(2):103662. doi: 10.1016/j.transci.2023.103662. Epub 2023 Feb 24. Transfus Apher Sci. 2023. PMID: 36842884 Review.
Does Total Body Irradiation Have a Favorable Impact on Thrombocyte Engraftment as per Neutrophil Engraftment in Allogeneic Stem Cell Transplantation?
Uncu Ulu B, Yiğenoğlu TN, Şahin D, Başcı S, İskender D, Adaş Y, Atasever Akkaş E, Hacıbekiroğlu T, Kızıl Çakar M, Dal MS, Altuntaş F. Uncu Ulu B, et al. Among authors: hacibekiroglu t. Cureus. 2021 Nov 11;13(11):e19462. doi: 10.7759/cureus.19462. eCollection 2021 Nov. Cureus. 2021. PMID: 34912605 Free PMC article.
Acute tubulointerstitial nephritis after COVID-19 m-RNA BNT162b2 vaccine.
Dheir H, Sipahi S, Cakar GC, Yaylaci S, Hacibekiroglu T, Karabay O. Dheir H, et al. Among authors: hacibekiroglu t. Eur Rev Med Pharmacol Sci. 2021 Oct;25(20):6171-6173. doi: 10.26355/eurrev_202110_26985. Eur Rev Med Pharmacol Sci. 2021. PMID: 34730195 Free article. No abstract available.
The Real-World Experience With Single Agent Ibrutinib in Relapsed/Refractory CLL.
Akpinar S, Dogu MH, Celik S, Ekinci O, Hindilerden IY, Dal MS, Davulcu EA, Tekinalp A, Hindilerden F, Ozcan BG, Hacibekiroglu T, Erkurt MA, Bagci M, Namdaroglu S, Korkmaz G, Bilgir O, Cagliyan GA, Ozturk HBA, Serin I, Tiryaki TO, Ozatli D, Korkmaz S, Ulas T, Eser B, Turgut B, Altuntas F. Akpinar S, et al. Among authors: hacibekiroglu t. Clin Lymphoma Myeloma Leuk. 2022 Mar;22(3):169-173. doi: 10.1016/j.clml.2021.09.010. Epub 2021 Sep 15. Clin Lymphoma Myeloma Leuk. 2022. PMID: 34629286
Efficacy and safety of plasmapheresis in symptomatic hyperviscosity and cast nephropathy: A Multicenter Experience in Turkey.
Kalpakci Y, Hacibekiroglu T, Darcin T, AkgunCagliyan G, Cakar MK, Hacioglu SK, Ekinci O, Korkmaz S, Albayrak M, Dal MS, Dogan A, Ulas T, Eser B, Altuntas F. Kalpakci Y, et al. Among authors: hacibekiroglu t. Transfus Apher Sci. 2021 Oct;60(5):103244. doi: 10.1016/j.transci.2021.103244. Epub 2021 Aug 25. Transfus Apher Sci. 2021. PMID: 34462219
Mesenchymal stem cell transfusion: Possible beneficial effects in COVID-19 patients.
Yiğenoğlu TN, Başcı S, Şahin D, Ulaş T, Dal MS, Korkmaz S, Hacıbekiroğlu T, Namdaroğlu S, Erkurt MA, Turgut B, Altuntaş F. Yiğenoğlu TN, et al. Among authors: hacibekiroglu t. Transfus Apher Sci. 2021 Dec;60(6):103237. doi: 10.1016/j.transci.2021.103237. Epub 2021 Aug 17. Transfus Apher Sci. 2021. PMID: 34419356 Free PMC article. Review.
37 results